Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZB001 in Chinese Patients with Thyroid-Associated Ophthalmopathy
NCT05776121Phase 1Completed
- Sponsor
- Zenas BioPharma
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of veligrotug in thyroid eye disease (TED) (2 arms), sponsored by Zenas BioPharma. Primary endpoints: Number of participants with Adverse Events, Serious Adverse Events, and Laboratory Evaluations and Exophthalmos response rates of study eye at Week 12. Started May 2023; status: completed.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05776121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776121.